American Portfolios Advisors’s AIM ImmunoTech AIM Stock Holding History

American Portfolios Advisors’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$133	Hold	2	–	–	﹤0.01%	3476
2022 Q2	$178	Hold	2	–	–	﹤0.01%	3468
2022 Q1	$242	Hold	2	–	–	﹤0.01%	3520
2021 Q4	$210	Hold	2	–	–	﹤0.01%	3461
2021 Q3	$461	Hold	2	–	–	﹤0.01%	3389
2021 Q2	$490	Hold	2	–	–	﹤0.01%	3322
2021 Q1	$518	Hold	2	–	–	﹤0.01%	3203
2020 Q4	$408	Hold	2	–	–	﹤0.01%	2914
2020 Q3	$490	Hold	2	–	–	﹤0.01%	2845
2020 Q2	$565	Hold	2	–	–	﹤0.01%	2753
2020 Q1	$584	Hold	2	–	–	﹤0.01%	2646
2019 Q4	$124	Hold	2	–	–	﹤0.01%	2790
2019 Q3	$174	Hold	2	–	–	﹤0.01%	2768
2019 Q2	$1K	Buy	+2	New	+$1.21K	﹤0.01%	2584

Other funds holding AIM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

American Portfolios Advisors's AIM Position: Q3 2022 in Review

American Portfolios Advisors held its AIM ImmunoTech (AIM) position steady in Q3 2022 at 2 shares worth $133. The position accounts for ﹤0.01% of the portfolio, ranked #3476.

American Portfolios Advisors first reported a position in AIM in Q2 2019 and has held it in 14 quarters since. The position peaked at $1K in Q2 2019. 34 funds tracked by Wall St. Rank hold AIM as of Q3 2022.

American Portfolios Advisors held 2 shares of AIM ImmunoTech worth $133 as of Q3 2022.
American Portfolios Advisors left its AIM ImmunoTech share count unchanged in Q3 2022.
AIM ImmunoTech made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #3476 holding.
American Portfolios Advisors first reported a position in AIM ImmunoTech in Q2 2019 and has held it in 14 quarters since.
American Portfolios Advisors's AIM ImmunoTech position peaked at $1K in Q2 2019.
34 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.